Exelixis Begins Groundbreaking Phase 1 Trial: New Bispecific Antibody Targets Advanced Cancer

Invenra Highlights Exelixis’ Initiation of Phase 1 Clinical Study Evaluating XB628, a First-in-Class Bispecific Antibody in Participants with Recurrent Advanced or Metastatic Solid Tumors

MADISON, Wis.--(BUSINESS WIRE)--May 13, 2025-

Exelixis (NASDAQ: EXEL) Tops Q1 Estimates, Raises 2025 Outlook; Shares Jump

Exelixis (NASDAQ: EXEL) shares jumped over 6% in pre-market trading on Wednesday after the company reported better-than-expected first-quarter results and lifted its full-year revenue outlook. Exelixis Stock Price Chart The biopharmaceutical company posted adjusted earnings of $0.62 per share, well above the analysts’ consensus estimate of $0.37. Revenue for the quarter reached $555.4 million, beating estimates of $495.3 million and marking a 30…

Exelixis Begins Groundbreaking Phase 1 Trial: New Bispecific Antibody Targets Advanced Cancer

Novel NK cell engager XB628 targets dual pathways in advanced tumors. First-in-class bispecific antibody enters clinical testing. See trial details.